Eyepoint, Inc.
A biopharmaceutical company that treats serious eye diseases with tiny, long-lasting implants placed in the eye. Its Durasert technology delivers steady doses of medication over months, powering products like YUTIQ for uveitis and DEXYCU for inflammation after cataract surgery. Founded in 1987 and long known as pSivida Corporation, it renamed itself EyePoint in 2018 after buying Icon Bioscience — the name a nod to its single-minded focus on the eye.
Bought 1.5K
Granted 7.5K
Granted 4.9K · Sold 4.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Duker Jay S.President and CEO, Director · 3 transactions | — | 356.8K | — | 1.5K | — |
| Elston GeorgeChief Financial Officer · 8 transactions | — | 240.3K | 7.5K | — | — |
| Ribeiro RamiroChief Medical Officer · 4 transactions | 0% | 2.4K | 4.9K | — | 4.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -3.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.